This compares to a 5-year survival rate of 93.2% for those not using a GLP-1 and a 10-year survival rate of 88.6%
Where Human Evidence Is Still Limited Human evidence is limited for injectable GHK-Cu, systemic anti-aging, hair loss treatment, chronic disease treatment, liver repair, cognitive benefit, and broad regenerative medicine claims
Allergies and Sensitivities: Some individuals may be allergic or sensitive to specific peptides or ingredients in peptide formulations
Victoza (liraglutide) injection, for subcutaneous use: prescribing information
Sci Signal (2010) 3(112):re3
It supports optimal cardiovascular function by helping regulate the bodys lipid metabolism, contributing to a healthy heart and circulatory system